Reporting of comparative effectiveness observational studies must follow the STROBE guidelines |
Authors should prepare a statistical analysis plan in advance |
To provide a more complete picture of effectiveness, several outcomes across multiple health domains should be compared |
Lost to follow-up from the study sample must be reported by the exposure of interest |
The proportion of patients who stop and/or change therapy over time, as well as the reasons for treatment discontinuation must be reported |
Covariates should be chosen based on subject matter knowledge and model selection should be justified |
The study baseline should be at treatment initiation and a description of how covariate measurements relate to baseline should be included |
The analysis should be based on all patients starting a treatment and not limited to patients remaining on treatment at a certain time point |
When treatment discontinuation occurs before the time of outcome assessment, this attrition should be taken into account in the analysis. |
Sensitivity analyses should be undertaken to explore the influence of assumptions related to missingness, particularly in case of attrition |